![Elenagen Changes Tumor Microenvironment](https://www.curelaboncology.com/wp-content/uploads/2019/11/change_curelab1.png")
Clinical Trials
The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen. The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients. Based on these successful results, we initiated Phase II Clinical Trials outside of the United States, and are now preparing Phase II Clinical Trials within the US.
Alexander
Shneider,
Ph.D.
Founder and CEO
BoD Chairman
Over 25 years of biotech and entrepreneurial experience. Currently Senior Research Fellow of molecular biology at University of Ariel, Israel; editorial board member for journals Aging and Cell Cycle. The past achievements and activities include but are not limited to drug development from concept to market authorization, patents in all major jurisdictions, advisory role for successful exits, consulting for Fortune 100 companies, establishing and leading international R&D consortia, senior authorship in papers and books.
Vlad
Gabai,
Ph.D.
VP of R&D
Over 30 years of successful discovery and development experience and problem-solving skills in R&D of anti-cancer drugs from bench to bedside. Over 80 papers, over 4,000 references. Past academic appointments with Boston University and Boston Biomedical Research Institute.
Gabriel Levin,
MD
Director of Oncology
Dr. Gabriel Levin is a gynecologic oncologist whose practice spans both surgery and systemic therapy for endometrial, ovarian, cervical, and vulvar cancers. He has managed patients across the full continuum of care—from diagnosis and staging to chemotherapy and participation in clinical trials—and brings hands-on experience in translational immuno-oncology. At CureLab Oncology, Dr. Levin leads clinical strategy for gynecologic malignancies, builds collaborations with leading centers, and supports the design and execution of multi-site studies evaluating Elenagen, the company’s DNA-based immunotherapy platform.
Charles
Legg
COO
Over 20 years of successful biotech and big pharma experience ranging from program & portfolio manager at the international pharmaceutical company, Shire Pharmaceuticals, to the first full-time employee of the gene therapy startup, Solid Ventures. Successful projects in molecular diagnostics, drug discovery from early POC to pivotal clinical trials, from commercial launching to global expansion, from early seed funding to two $100MM+ IPOs. Focus on gene therapy and immuno-oncology.
Ilya Lapshin,
JD
General Counsel
Ricarda Cramer,
MBA
Director of Business Development, EU
Jihad A.
Fakhreddine
Director of Business Development, GCC
Vlad
Zayets-Volshin
Director of Business Development, Eurasia
